BrightSpring Q2 Revenue Jumps 23%, Net Income Soars to $87M; Full-Year Guidance Raised

summarizeSummary

BrightSpring Health Services reported Q2 2026 results that crushed year-ago figures — revenue up 23%, net income of $87M vs $9M — and raised full-year guidance across the board. The quarter also featured a $300M debt paydown and lower leverage.

check_boxKey Events · Earnings and Guidance · BTSG

• Q2 Revenue +23%, Net Income $87M

  Revenue reached $3,873 million, up 23.0% year-over-year, driven by 22% growth in Pharmacy Solutions and 30% growth in Provider Services. Net income from continuing operations was $86.6 million, compared to just $8.5 million a year ago.

• Adjusted EBITDA Surges 44%

  Adjusted EBITDA hit $206 million, a 44.2% increase from $143 million in Q2 2025, with segment EBITDA up 41% and corporate costs well controlled.

• Full-Year Guidance Raised

  Management lifted 2026 revenue guidance to $15.1–$15.425 billion (17–19.5% growth) and Adjusted EBITDA to $820–$845 million (32.8–36.8% growth), reflecting strong momentum and the Amedisys/LHC branches acquisition contribution.

• Balance Sheet Strengthened

  Leverage improved to 2.15x from 2.27x at March 31, 2026, following a $300 million paydown and modification of the First Lien Facility that also reduced interest costs.

auto_awesomeAnalysis · BTSG · Industrial Applications And Services

BrightSpring delivered a standout quarter, with revenue up 23% and net income surging nearly tenfold to $87 million. Adjusted EBITDA grew 44%, and the company raised its full-year revenue and profit outlook well above prior expectations. The balance sheet also strengthened — leverage fell to 2.15x after a $300 million debt paydown and interest-rate refinancing. This is a clear beat-and-raise quarter that confirms the business is firing on all cylinders following the Community Living divestiture.